Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Teduglutide recombinant
Drug ID BADD_D02138
Description Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Indications and Usage Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.
Marketing Status Not Available
ATC Code A16AX08
DrugBank ID DB08900
KEGG ID D06053
MeSH ID C494910
PubChem ID 70683012
TTD Drug ID D00RCI
NDC Product Code 41524-0009; 68875-0103; 68225-087; 68875-0101; 17337-0264; 63557-1031; 68594-001; 68875-0102
Synonyms teduglutide | Gly(2)-GLP-2 | (Gly2)GLP-2
Chemical Information
Molecular Formula C164H252N44O55S
CAS Registry Number 197922-42-2
SMILES CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C (CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O )N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O) C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(= O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(C C(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C NC(=O)C(CC5=CNC=N5)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
SarcomaInsulin-like growth factor IP05019T60930Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
C-reactive protein increased13.09.01.007--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Cholecystitis09.03.01.001--
Cholestasis09.01.01.001--Not Available
Cough22.02.03.001--
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspnoea02.01.03.002; 22.02.01.004--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site haematoma12.07.03.004; 08.02.03.004; 24.07.01.009--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Intestinal obstruction07.13.01.002--Not Available
Loss of consciousness17.02.04.004--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Pancreatitis07.18.01.001--
Paraesthesia17.02.06.005--
The 1th Page    1 2    Next   Last    Total 2 Pages